{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:32:49Z","timestamp":1791268369798,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,5,31]],"date-time":"2010-05-31T00:00:00Z","timestamp":1275264000000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["PM&amp;R"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p>Fatigue is a common side effect of medications. This review summarizes some of the mechanisms by which drugs may cause fatigue. One major mechanism by which medications can cause fatigue is by central nervous system (CNS) depression. CNS depression can result from decreased excitatory activity, as is commonly seen with some anticholinergic agents, centrally acting \u03b1\u2010agonists, and anticonvulsants. CNS depression can also result from increased inhibitory activity within the CNS, as is seen with benzodiazepines and barbiturates, which augment the effects of the inhibitory neurotransmitter, gamma\u2010aminobutyric acid. Opioids also increase inhibitory CNS activity through their interactions with the various subtypes of opioid receptors. Acting outside of the CNS, medications may cause fatigue as a result of either a true or a functional anemia by a number of mechanisms. Bone marrow toxicity, which results in decreased hematopoiesis, is such a mechanism. This is commonly seen with antineoplastics agents, but can also be observed in association with a wide variety of medication classes, including anticonvulsants, antidepressants, and antimicrobial agents. Another way that medications can cause anemia is by increased red blood cell destruction, as is seen with immune hemolytic anemia. Additionally, medications may cause a functional anemia through alteration of the heme group within the hemoglobin molecule, as is seen in methemoglobinemia. Finally, many drugs, including placebos, cause fatigue by unknown mechanisms. In addition to causing fatigue, some medications may be used to help relieve fatigue, although this drug class is limited in number at this point in time.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.pmrj.2010.04.018","type":"journal-article","created":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T12:43:47Z","timestamp":1275396227000},"page":"451-455","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Mechanisms by Which Pharmacologic Agents May Contribute to Fatigue"],"prefix":"10.1002","volume":"2","author":[{"given":"Daniel A.","family":"Zlott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,5,31]]},"reference":[{"key":"e_1_2_8_2_2","unstructured":"AHFS Drug Information 2006 2006 The American Society of Health\u2010System Pharmacists Inc Bethesda MD"},{"key":"e_1_2_8_3_2","volume-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","author":"Hardman J.G.","year":"2001"},{"key":"e_1_2_8_4_2","unstructured":"MICROMEDEX Healthcare Series DRUGDEX Evaluations 2009 Thomson Scopolamine"},{"key":"e_1_2_8_5_2","volume-title":"Lexi\u2010Comp Online","year":"2009"},{"key":"e_1_2_8_6_2","volume-title":"AHFS Drug Information 2006","author":"AHFS","year":"2006"},{"key":"e_1_2_8_7_2","volume-title":"AHFS Drug Information 2006","author":"AHFS","year":"2006"},{"key":"e_1_2_8_8_2","unstructured":"AHFS Drug Information 2006 2006 The American Society of Health\u2010System Pharmacists Inc Bethesda MD"},{"key":"e_1_2_8_9_2","unstructured":"MICROMEDEX Healthcare Series DRUGDEX Evaluations 2009 Thomson Clonidine"},{"key":"e_1_2_8_10_2","unstructured":"Lexi\u2010Comp Online 2009 Lexi\u2010Comp Inc Clonidine"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp08X299317"},{"key":"e_1_2_8_12_2","unstructured":"AHFS Drug Information 2006 2006 The American Society of Health\u2010System Pharmacists Inc Bethesda MD"},{"key":"e_1_2_8_13_2","unstructured":"AHFS Drug Information 2006 2006 The American Society of Health\u2010System Pharmacists Inc Bethesda MD"},{"key":"e_1_2_8_14_2","unstructured":"MICROMEDEX Healthcare Series DRUGDEX Evaluations 2009 Thomson Phenytoin"},{"key":"e_1_2_8_15_2","unstructured":"Lexi\u2010Comp Online 2009 Lexi\u2010Comp Inc Phenytoin"},{"key":"e_1_2_8_16_2","unstructured":"MICROMEDEX Healthcare Series DRUGDEX Evaluations 2009 Thomson Carbamazepine"},{"key":"e_1_2_8_17_2","unstructured":"Lexi\u2010Comp Online 2009 Lexi\u2010Comp Inc Carbamazepine"},{"key":"e_1_2_8_18_2","unstructured":"MICROMEDEX Healthcare Series DRUGDEX Evaluations 2009 Thomson Ethosuximide"},{"key":"e_1_2_8_19_2","unstructured":"Lexi\u2010Comp Online: Ethosuximide 2009 Lexi\u2010Comp Inc"},{"key":"e_1_2_8_20_2","volume-title":"Vaplroic acid","author":"MICROMEDEX Healthcare Series DRUGDEX Evaluations","year":"2009"},{"key":"e_1_2_8_21_2","unstructured":"Lexi\u2010Comp Online: Valproic acid and derivatives 2009 Lexi\u2010Comp Inc"},{"key":"e_1_2_8_22_2","unstructured":"AHFS Drug Information 2006 2006 The American Society of Health\u2010System Pharmacists Inc Bethesda MD"},{"key":"e_1_2_8_23_2","unstructured":"AHFS Drug Information 2006 2006 The American Society of Health\u2010System Pharmacists Inc Bethesda MD"},{"key":"e_1_2_8_24_2","unstructured":"MICROMEDEX Healthcare Series DRUGDEX Evaluations 2009 Thomson Albendazole"},{"key":"e_1_2_8_25_2","volume-title":"Albendazole","author":"Lexi\u2010Comp Online","year":"2009"},{"key":"e_1_2_8_26_2","volume-title":"AHFS Drug Information 2006","author":"AHFS","year":"2006"},{"key":"e_1_2_8_27_2","unstructured":"MICROMEDEX Healthcare Series DRUGDEX Evaluations 2009 Thomson Ivermectin"},{"key":"e_1_2_8_28_2","unstructured":"Lexi\u2010Comp Online 2009 Lexi\u2010Comp Inc Ivermectin"},{"key":"e_1_2_8_29_2","volume-title":"AHFS Drug Information 2006Bethesda, MD","author":"AHFS","year":"2006"},{"key":"e_1_2_8_30_2","unstructured":"MICROMEDEX Healthcare Series DRUGDEX Evaluations 2009 Thomson Praziquantel"},{"key":"e_1_2_8_31_2","unstructured":"Lexi\u2010Comp Online 2009 Lexi\u2010Comp Inc Praziquentel"},{"key":"e_1_2_8_32_2","first-page":"1","article-title":"Interferon\u2010alpha effects on diurnal hypothalamic\u2010pituitary\u2010adrenal axis activity: Relationship with proinflammatory cytokines and behavior","volume":"15","author":"Raison C.","year":"2008","journal-title":"Mol Psychol"},{"key":"e_1_2_8_33_2","volume-title":"Comrehensive Toxicology","author":"Bloom J.","year":"1977"},{"key":"e_1_2_8_34_2","volume-title":"Emergency Medicine: Concepts and Clinical Practice4th ed","author":"Curry S.","year":"1997"},{"key":"e_1_2_8_35_2","volume-title":"Hematology Basic Principles and Practice","author":"Hoffman R.","year":"2005"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2004.02.001"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2009.80.188"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-75-1-83"},{"key":"e_1_2_8_39_2","volume-title":"Cecil Medicine","author":"Schwartz R.","year":"2007"},{"key":"e_1_2_8_40_2","unstructured":"AHFS Drug Information 2006 2006 The American Society of Health\u2010System Pharmacists Inc Bethesda MD"}],"container-title":["PM&amp;R"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.pmrj.2010.04.018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1934148210003382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1934148210003382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.pmrj.2010.04.018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:17:46Z","timestamp":1694726266000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1016\/j.pmrj.2010.04.018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1016\/j.pmrj.2010.04.018"],"URL":"https:\/\/doi.org\/10.1016\/j.pmrj.2010.04.018","archive":["Portico"],"relation":{},"ISSN":["1934-1482","1934-1563"],"issn-type":[{"value":"1934-1482","type":"print"},{"value":"1934-1563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"2010-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-04-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-05-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}